Diligence memo · auto-generated · as of July 2, 2026
Zafrens Inc.
Zafrens Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Zafrens Inc. operates in Pharmaceuticals, based in SAN DIEGO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Zafrens Inc. has raised $6.2M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $6.2M on 2021-12-29.
Most recent recorded round closed around 2021-12-29.
Valuation (modeled)modeled
Provath models Zafrens Inc. at approximately $98M (range $7.1M–$376M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.64× the median modeled value of Series A Pharmaceuticals companies in 2019–2021 (76 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 4.5 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 46% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 54% of those peers.
Closest niche peers: Xynomic Pharmaceuticals Holdings, Inc., Honest Globe Inc., Athenen Therapeutics, Inc., Zomedica Pharmaceuticals Corp., CerSci Therapeutics Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.